Prix
GRAPH PAR
Questions fréquentes
Quelle est la capitalisation boursière de Attovia Therapeutics, Inc. ?
Quelles sont les évaluations des analystes et le prix cible de l'action Attovia Therapeutics, Inc. ?
Quel est le flottant des actions de Attovia Therapeutics, Inc. ?
Finances
- Capitalisation boursière
- 975,39 M $US
- Free Float
- 27,34 M
Cotation
- 52W span
- 16,20 $US24,25 $US
Notes des analystes
L'objectif de prix est de 42,20 $US et l'action est analysée par 5 analystes.
Acheter
5
Hold
0
Vendre
0
Informations
Attovia Therapeutics, Inc. is a biopharmaceutical company developing precision multispecific biologics to address immune-mediated and inflammatory diseases, including dermatology conditions such as atopic dermatitis and chronic pruritus, and gastroenterology disorders like inflammatory bowel disease. The company is based in San Carlos, CA. The company utilizes its proprietary Attobody™ platform to design novel multispecific molecules that inhibit multiple disease-driving pathways. Key pipeline candidates include ATTO-1310 (anti-IL31) and ATTO-3712 (anti-IL31 x IL13), both in phase 1 clinical trials for chronic pruritus and inflammatory skin disease, and ATTO-1091, a trispecific molecule in IND-enabling stages for inflammatory bowel disease. The company was founded in 2022 by Petter Veiby, Tao Fu, Zaneta Odrowaz. Tao Fu has been the CEO of the company since 2022.
- Industries
- Biotechnologie
- Secteur
- Soins de santé
Identifiant
- Ticker primaire
- ATTO